AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2021
Sep 15, 2021
30849_dirs_2021-09-15_162bc533-c9d0-4a62-a287-1e08690738de.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2021-09-10
Reporting Person: Manning Linda Shapiro (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-09-10 | Stock Option (Right to Buy) | $12.98 | A | 15000 | Acquired | 2031-09-09 | Common Stock (15000) | Direct |
| 2021-09-10 | Restricted Stock Units | $ | A | 2500 | Acquired | Common Stock (2500) | Direct |
Footnotes
F1: The stock options were granted on September 10, 2021. 25% of the shares subject to the option will vest and become exercisable on September 10, 2022 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F3: The restricted stock units vest as to 25% of the total shares on each of September 10, 2022, September 10, 2023, September 10, 2024 and September 10, 2025. The restricted stock units have no expiration date.